Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) ...

Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.

WATERTOWN, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, today announced they will ...

Cure HHT has led the development of the first international consensus on how to define, measure, and track bleeding in Hereditary Hemorrhagic Telangiectasia (HHT), published July 15 in the American ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. ST. LOUIS – A new, highly-specialized, ...

Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...

FORT IRWIN, Calif. - In the modern Army, there are many ways to be a Soldier, but on the battlefield a Soldier without a weapon is ineffective. Weapon familiarity and maintenance can be the deciding ...